
OST-HER2 shows 71.2% 3-year survival in osteosarcoma, beating 45.8% control, aiming for 2027 market approval.
OS Therapies announced that their OST-HER2 immunotherapy achieved a 71.2% three-year overall survival rate in a Phase 2b trial for metastatic osteosarcoma, significantly higher than the 45.8% survival in historical controls (p=0.002). This promising ...

